AIM ImmunoTech Inc - Company Profile
Powered by 
All the sales intelligence you need on AIM ImmunoTech Inc in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how AIM ImmunoTech Inc fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with AIM ImmunoTech Inc.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
AIM ImmunoTech Inc (AIM) is an immuno-pharma company that focuses on the research and development of therapeutics for treating various cancers, viral diseases, and immune-deficiency disorders. The company's major products include Ampligen (rintatolimod) and Alferon N Injection (Interferon alfa). Ampligen is a double-stranded RNA molecule being developed for cancers, viral diseases, and immune system disorders and is approved for commercial sale in Argentina for severe chronic fatigue syndrome. AIM ImmunoTech's products are used in clinical trials for applications such as pancreatic cancer, myalgic encephalomyelitis/chronic fatigue syndrome, and as a vaccine adjuvant. The company collaborates with research organizations like Amarex Clinical Research. It operates in various international markets, with clinical activities in the Netherlands and Argentina. AIM ImmunoTech is headquartered in Ocala, Florida, the US.
Headquarters
United States of America
Address
2117 Sw Highway 484, Ocala, Florida, 32801
Website
wwws.aimimmuno.com
Telephone
1 352 4487797
No of Employees
19
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
AIM (AFM)
Revenue (2024)
$88,000
-48.2%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
19.4%
(2024 vs 2023)
Market Cap*
$6.7M
Net Profit Margin (2024)
XYZ
-55.7%
(2024 vs 2023)
* As of and is in US$
AIM ImmunoTech Inc premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Rintatolimod - Chronic Fatigue Syndrome | Ampligen |
| Alferon N Injection- Refractory to Recombinant IFN | Alferon N Injection |
| Alferon N Injection- Intolerant to Recombinant IFN | |
| XYZ | |
| XYZ | |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2024 | Patent Grant | In December, the company was granted a patent for Ampligen by the Netherlands Patent Office. |
| 2024 | Patent Grant | In October, the company received a US patent for Ampligen to treat endometriosis, affecting 6.5 million women in the US. |
| 2022 | Regulatory Approval | In October, the company secured approval from U.S. Food and Drug Administration (FDA) of IND application to evaluate Ampligen in phase 2 clinical study for the treatment of post-COVID conditions. |
Competitor Comparison
| Key Parameters | AIM ImmunoTech Inc | Merck & Co Inc | Pfizer Inc | Novartis AG | GSK plc |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | Switzerland | United Kingdom |
| City | Ocala | Rahway | New York City | Basel | London |
| State/Province | Florida | New Jersey | New York | Basel-Stadt | England |
| No. of Employees | 19 | 75,000 | 75,000 | 75,267 | 66,841 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| William M. Mitchell, M.D., Ph.D. | Chairman | Executive Board | 2016 | 90 |
| Thomas K. Equels | President; Vice Chairman; Chief Executive Officer | Senior Management | - | 73 |
| Robert Dickey IV | Chief Financial Officer | Senior Management | 2022 | 70 |
| Peter W. Rodino III | Secretary; Chief Operating Officer; General Counsel | Senior Management | 2019 | 74 |
| Christopher Nicodemus, M.D. | Consulting Science Officer | Senior Management | - | - |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer